Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose

Clinical Science

Volumn 122, Issue 4, 2012, Pages 193-202

  Perlstein, Todd S ^a   Henry, Robert R ^b   Mather, Kieren J ^c   Rickels, Michael R ^d   Abate, Nicola I ^e   Grundy, Scott M ^f   Mai, Yabing ^g   Albu, Jeanine B ^h   Marks, Jennifer B ⁱ   Pool, James L ^j   Creager, Mark A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

^h ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^j Baylor Clinic   (United States)

more..

Author keywords

Angiotensin II; Clinical trial; Hypertension; Insulin signalling; Obesity; Vascular function

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; ISOPROSTANE DERIVATIVE; LOSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CREATININE; POTASSIUM;

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPEREMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISORDERS OF CARBOHYDRATE METABOLISM; HEART RATE; MIDDLE AGED; VASCULAR ENDOTHELIUM; VASODILATATION;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; CREATININE; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; GLUCOSE METABOLISM DISORDERS; HEART RATE; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; OBESITY, ABDOMINAL; POTASSIUM; VASODILATION;

EID: 84555205605     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20110284     Document Type: Article

References (44)

1. Olshansky, S. J., Passaro, D. J., Hershow, R. C., Layden, J., Carnes, B. A., Brody, J., Hayflick, L., Butler, R. N., Allison, D. B. and Ludwig, D. S. (2005) A potential decline in life expectancy in the United States in the 21st century. N. Engl. J. Med. 352, 1138-1145
2. Kim, J. A., Montagnani, M., Koh, K. K. and Quon, M. J. (2006) Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113, 1888-1904
3. Calegari, V. C., Alves, M., Picardi, P. K., Inoue, R. Y., Franchini, K. G., Saad, M. J. and Velloso, L. A. (2005) Suppressor of cytokine signaling-3 provides a novel interface in the cross-talk between angiotensin II and insulin signaling systems. Endocrinology 146, 579-588
4. 616 in human umbilical vein endothelial cells. Circ. Res. 94, 1211-1218
5. Rajagopalan, S., Kurz, S., Munzel, T., Tarpey, M., Freeman, B. A., Griendling, K. K. and Harrison, D. G. (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 97, 1916-1923
6. Wassmann, S., Czech, T., van Eickels, M., Fleming, I., Bohm, M. and Nickenig, G. (2004) Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation 110, 3062-3067
7. Hsieh, P. S. (2005) Reversal of fructose-induced hypertension and insulin resistance by chronic losartan treatment is independent of AT2 receptor activation in rats. J. Hypertens. 23, 2209-2217
8. Pickering, T. G., Hall, J. E., Appel, L. J., Falkner, B. E., Graves, J., Hill, M. N., Jones, D.W., Kurtz, T., Sheps, S. G. and Roccella, E. J. (2005) Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 111, 697-716
9. Nohria, A., Gerhard-Herman, M., Creager, M. A., Hurley, S., Mitra, D. and Ganz, P. (2006) Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. J. Appl. Physiol. 101, 545-548
10. DeFronzo, R. A., Tobin, J. D. and Andres, R. (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 237, E214-E223
11. Rizza, R. A., Mandarino, L. J. and Gerich, J. E. (1981) Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am. J. Physiol. 240, E630-E639
12. Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F. and Turner, R. C. (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419
13. Moan, A., Hoieggen, A., Nordby, G., Eide, I. K. and Kjeldsen, S. E. (1995) Effects of losartan on insulin sensitivity in severe hypertension: connections through sympathetic nervous system activity? J. Hum. Hypertens. (Suppl. 5), S45-S50
14. Paolisso, G., Tagliamonte, M. R., Gambardella, A., Manzella, D., Gualdiero, P., Varricchio, G., Verza, M. and Varricchio, M. (1997) Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J. Hum. Hypertens. 11, 307-312
15. Cheetham, C., Collis, J., O'Driscoll, G., Stanton, K., Taylor, R. and Green, D. (2000) Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. J. Am. Coll. Cardiol. 36, 1461-1466
16. Cheetham, C., O'Driscoll, G., Stanton, K., Taylor, R. and Green, D. (2001) Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in Type II diabetes. Clin. Sci. 100, 13-17
17. Deng, Y. B., Wang, D.W., Li, C. L. and Yang, H. Y. (2002) Effects of the angiotensin receptor antagonist losartan on the response of the left main coronary artery to cold pressor test in patients with essential hypertension as assessed by echocardiography. Can. J. Cardiol. 18, 389-396
18. Deng, Y. B., Yang, H. Y., Li, C. L. and Chang, Q. (2002) Angiotensin receptor antagonist losartan improves endothelial function of epicardial coronary arteries in patients with essential hypertension. Clin. Cardiol. 25, 422-428
19. Perlstein, T. S., Gerhard-Herman, M., Hollenberg, N. K., Williams, G. H. and Thomas, A. (2007) Insulin induces renal vasodilation, increases plasma renin activity, and sensitizes the renal vasculature to angiotensin receptor blockade in healthy subjects. J. Am. Soc. Nephrol. 18, 944-951
20. Liu, J., Wang, J., Jin, Y., Roethig, H. J. and Unverdorben, M. (2009) Variability of peripheral arterial tonometry in the measurement of endothelial function in healthy men. Clin. Cardiol. 32, 700-704
21. Oparil, S., Abate, N., Chen, E., Creager, M. A., Galet, V., Jia, G., Julius, S., Lerman, A., Lyle, P. A., Pool, J. and Tershakovec, A. M. (2008) A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension. Curr. Med. Res. Opin. 24, 1101-1114
22. Folli, F., Kahn, C. R., Hansen, H., Bouchie, J. L. and Feener, E. P. (1997) Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J. Clin. Invest. 100, 2158-2169
23. Izawa, Y., Yoshizumi, M., Fujita, Y., Ali, N., Kanematsu, Y., Ishizawa, K., Tsuchiya, K., Obata, T., Ebina, Y., Tomita, S. and Tamaki, T. (2005) ERK1/2 activation by angiotensin II inhibits insulin-induced glucose uptake in vascular smooth muscle cells. Exp. Cell Res. 308, 291-299
24. Taniyama, Y., Hitomi, H., Shah, A., Alexander, R. W. and Griendling, K. K. (2005) Mechanisms of reactive oxygen species-dependent downregulation of insulin receptor substrate-1 by angiotensin II. Arterioscler. Thromb. Vasc. Biol. 25, 1142-1147
25. Moan, A., Hoieggen, A., Seljeflot, I., Risanger, T., Arnesen, H. and Kjeldsen, S. E. (1996) The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J. Hypertens. 14, 1093-1097
26. Aksnes, T. A., Reims, H. M., Guptha, S., Moan, A., Os, I. and Kjeldsen, S. E. (2006) Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors. J. Hum. Hypertens. 20, 860-866
27. Nishimura, H., Sanaka, T., Tanihata, Y., Naito, T., Higuchi, C. and Otsuka, K. (2008) Losartan elevates the serum high-molecular weight-adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism. Hypertens. Res. 31, 1611-1618
28. Jin, H. M. and Pan, Y. (2007) Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. Nephrol. Dial. Transplant. 22, 1943-1949
29. Laakso, M., Karjalainen, L. and Lempiainen-Kuosa, P. (1996) Effects of losartan on insulin sensitivity in hypertensive subjects. Hypertension 28, 392-396
30. Fogari, R., Zoppi, A., Corradi, L., Lazzari, P., Mugellini, A. and Lusardi, P. (1998) Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. Br. J. Clin. Pharmacol. 46, 467-471
31. Fogari, R., Zoppi, A., Lazzari, P., Preti, P., Mugellini, A., Corradi, L. and Lusardi, P. (1998) ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J. Cardiovasc. Pharmacol. 32, 616-620
32. Fogari, R., Zoppi, A., Preti, P., Fogari, E., Malamani, G. and Mugellini, A. (2001) Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. Am. J. Hypertens. 14, 921-926
33. Gillespie, E. L., White, C. M., Kardas, M., Lindberg, M. and Coleman, C. I. (2005) The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 28, 2261-2266
34. Santoro, D., Natali, A., Palombo, C., Brandi, L. S., Piatti, M., Ghione, S. and Ferrannini, E. (1992) Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension. Hypertension 20, 181-191
35. Tikellis, C., Wookey, P. J., Candido, R., Andrikopoulos, S., Thomas, M. C. and Cooper, M. E. (2004) Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 53, 989-997
36. Carlsson, P. O., Berne, C. and Jansson, L. (1998) Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 41, 127-133
37. Ko, S. H., Kwon, H. S., Kim, S. R., Moon, S. D., Ahn, Y. B., Song, K. H., Son, H. S., Cha, B. Y., Lee, K. W., Son, H. Y. et al. (2004) Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats. Biochem. Biophys. Res. Commun. 316, 114-122
38. Suzuki, K., Nakagawa, O. and Aizawa, Y. (2008) Improved early-phase insulin response after candesartan treatment in hypertensive patients with impaired glucose tolerance. Clin. Exp. Hypertens. 30, 309-314
39. Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D. and Alexander, R. W. (1994) Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74, 1141-1148
40. Haas, J. A., Krier, J. D., Bolterman, R. J., Juncos, L. A. and Romero, J. C. (1999) Low-dose angiotensin II increases free isoprostane levels in plasma. Hypertension 34, 983-986
41. Creager, M. A. and Roddy, M. A. (1994) Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 24, 499-505
42. Koh, K. K., Han, S. H., Chung, W. J., Ahn, J. Y., Jin, D. K., Kim, H. S., Park, G. S., Kang, W. C., Ahn, T. H. and Shin, E. K. (2004) Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. Am. J. Cardiol. 93, 1432-1435
43. Bonetti, P. O., Barsness, G. W., Keelan, P. C., Schnell, T. I., Pumper, G. M., Kuvin, J. T., Schnall, R. P., Holmes, D. R., Higano, S. T. and Lerman, A. (2003) Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J. Am. Coll. Cardiol. 41, 1761-1768
44. Alvarez, A., Cerda-Nicolas, M., Naim Abu Nabah, Y., Mata, M., Issekutz, A. C., Panes, J., Lobb, R. R. and Sanz, M. J. (2004) Direct evidence of leukocyte adhesion in arterioles by angiotensin II. Blood 104, 402-408